Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.
Commentary|Articles|July 29, 2026
Detecting Alzheimer Disease Pathology Before Symptoms Emerge
Fact checked by: Marco Meglio
Experts discuss how plasma biomarkers may enable earlier detection of Alzheimer disease pathology, including in cognitively unimpaired individuals and those with subjective cognitive decline, while offering a more accessible alternative to CSF and PET-based assessment. [WATCH TIME: 8 Minutes]
Advertisement
Advertisement
WATCH TIME: 8 minutes | Captions are auto-generated and may contain errors.
Related to this article
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.
The Editor-in-Chief of the Journal of the American Heart Association discussed what journal editors look for in stroke research submissions, how AI and open access are reshaping publishing, and the equity gaps that still exist for researchers in lower-income countries.
Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.
New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.
Here's some of what is coming soon to NeurologyLive® this week.
A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.
Advertisement
Advertisement